回复信：“SARS-CoV-2 疫苗在遗传性果糖不耐受成年患者中的安全性”。
Reply letter to "safety of SARS-Cov-2 vaccines administration for adult patients with hereditary fructose intolerance".
机构信息
Paediatric Gastroenterology, Hepatology and Nutrition Unit, Department of Paediatrics, University Clinical Hospital, Santiago de Compostela, Spain.
Unit of Diagnosis and Treatment of Congenital Metabolic Diseases, Department of Paediatrics, University Clinical Hospital, Santiago de Compostela, Spain.
出版信息
Hum Vaccin Immunother. 2021 Nov 2;17(11):4115-4116. doi: 10.1080/21645515.2021.1959149. Epub 2021 Sep 2.
In the letter, Urro et al. performed a search on the sucrose, fructose and sorbitol content in the approved Sars-Cov-2 vaccines and they concluded that these vaccines can be safely administered in adults affected by Hereditary fructose intolerance.The Pfizer-BioNTech COVID-19 Vaccine is currently approved for use in adolescents ≥ 12 years and the Moderna COVID-19 vaccine is close to approval for use in children over 12 years of age. Furthermore, both vaccines have initiated clinical trials that will include infant as young as 6 months. Therefore, we considerate important to analyze the safely administration of this two vaccines in children with Hereditary fructose intolerance.
在这封信中，Urro 等人对已批准的 SARS-CoV-2 疫苗中的蔗糖、果糖和山梨糖醇含量进行了检索，他们的结论是，这些疫苗可以安全地用于遗传性果糖不耐受的成年人。辉瑞-生物技术公司的 COVID-19 疫苗目前已获准用于 12 岁及以上青少年使用，而 Moderna COVID-19 疫苗也即将获准用于 12 岁以上儿童使用。此外，这两种疫苗都已启动临床试验，将包括 6 个月大的婴儿。因此，我们认为有必要分析这两种疫苗在遗传性果糖不耐受儿童中的安全性。
Zotero 插件